Advertisement

Topics

Merck and Co Research

04:03 EST 16th February 2019 | BioPortfolio

Doravirine: First Global Approval.

Doravirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Merck & Co for the treatment of HIV-1 infection. The drug is approved in the USA both as a single-agent tablet (Pifeltro™) and as a fixed-dose combination tablet with the nucleos(t)ide reverse transcriptase inhibitors lamivudine and tenofovir disoproxil fumarate (Delstrigo™). Each formulation is indicated i...

Co-crystallization of human inositol monophosphatase with the lithium mimetic L-690,330.

Lithium, which is still the gold standard in the treatment of bipolar disorder, has been proposed to inhibit inositol monophosphatase (IMPase) and is hypothesized to exert its therapeutic effects by attenuating phosphatidylinositol (PI) cell signalling. Drug-discovery efforts have focused on small-molecule lithium mimetics that would specifically inhibit IMPase without exhibiting the undesired sid...

Merck vaccine heads Ebola countermeasures.

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Merck and Co market research data and corporate reports here